Thursday, May 9, 2013
The Structural Genomics Consortium is spearheading the three-year Structure-guided Drug
Discovery Consortium, which aims to bring pharma-quality medicinal chemistry
capabilities to targets against malaria and tuberculosis. With a 3-year, $5
million grant from the Bill &
Melinda Gates Foundation and another $10 million in
supporting funds already available to its members, the drug discovery
consortium will focus on projects that put early stage therapeutic assets in
the hands of its key product development partners-Medicines for Malaria Venture
and the Global Alliance for TB Drug Development.
From targets to leads
SDDC is working with its product
development partners, sponsors and consultants who work in these disease spaces
to sift through a portfolio of about 20-30 TB targets and 15 malaria targets.
The Global Alliance for TB Drug
Development and Medicines for Malaria Venture (MMV) see SDDC as a vehicle for
augmenting their respective drug discovery pipelines.
K.-J. SciBX 6(18);
Published online May 9, 2013
AND INSTITUTIONS MENTIONED
Bill & Melinda Gates Foundation, Seattle, Wash.
Center for Structural Genomics of Infectious Diseases, Evanston, Ill.
Global Alliance for TB Drug Development, New York, N.Y.
Medicines for Malaria Venture, Geneva, Switzerland
Midwest Center for Structural Genomics, Argonne, Ill.
National Institutes of Health, Bethesda, Md.
Seattle Structural Genomics Center for Infectious Disease, Seattle, Wash.
Structural Genomics Consortium, Toronto, Ontario, Canada
TB Structural Genomics Consortium, Los Angeles, Calif.